Cellectar Biosciences, Inc. — Q3 2017 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2017. Cellectar is a clinical-stage biopharmaceutical company developing cancer therapies using its phospholipid drug conjugate (PDC) platform. Its lead candidate, CLR 131, was in Phase 1 and Phase 2 studies. The filing reports no product revenue.
Financial results and position
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Research and development | $2.33 million | $1.31 million | $6.37 million | $3.31 million |
| General and administrative | $1.15 million | $1.16 million | $3.15 million | $3.49 million |
| Total costs and expenses / operating loss | $3.48 million | $2.47 million | $9.51 million | $6.80 million |
| Net loss | $3.47 million | $2.29 million | $9.48 million | $3.60 million |
| Basic and diluted loss per share | $0.26 | $0.43 | $0.73 | $1.02 |
At September 30, 2017, cash and cash equivalents were $5.66 million, down from $11.44 million at December 31, 2016. Total current assets were $6.69 million; current liabilities were $2.13 million. Total liabilities were $2.28 million, including $110,500 of derivative liabilities and $6,190 of capital lease obligations. Notes payable were zero; the Wisconsin Economic Development Corporation loans were paid in full during Q1.
For the first nine months, operating cash outflow was $8.19 million, investing cash outflow was $347,000, and financing cash inflow was $2.76 million, principally from warrant exercises. The company reported no gross margin; the filing does not provide a clear standalone margin measure.
Material changes versus comparable periods
- Nine-month R&D expense rose 92% to $6.37 million, mainly due to the CLR 131 Phase 2 study and expanded manufacturing and supplier capabilities; personnel and preclinical services also contributed.
- Nine-month G&A expense declined 10% to $3.15 million, primarily from lower legal, accounting, and consulting costs.
- Nine-month net loss increased substantially from 2016, when results included a $3.20 million gain on derivative warrant revaluation; the comparable 2017 gain was only $17,000.
- Weighted-average shares for the nine-month period increased to 12.99 million from 3.54 million. At September 30, 8.73 million warrants and 934,562 options and grants were excluded from diluted EPS as anti-dilutive.
Outlook, developments, and risks
- Management said September cash plus proceeds from the October 2017 financing was expected to fund operations for the next 12 months. The October offering generated approximately $7.76 million gross and $7.0 million net, and included common shares, preferred stock, and warrants. Management said additional funding would be needed beyond that period and planned to pursue financing in 2018; no such transaction was then under negotiation.
- CLR 131 Phase 1 Cohort 4 results announced in September showed one partial response among three patients at 31.25 mCi/m²; the other two had stable disease. The company had initiated a Phase 2 study using a 25.0 mCi/m² dose, with potential dose adjustment based on ongoing results.
- The company expects operating losses to continue and has no product revenues. Key risks include clinical or preclinical failure, regulatory and manufacturing hurdles, competition, and inability to raise capital on acceptable terms. A funding shortfall could delay, reduce, or end development programs or require partnering that relinquishes economic or proprietary rights.
- The October financing included Series D warrants exercisable for 3,108,538 shares at $1.78 per share, creating potential dilution. The filing’s descriptions of the preferred-stock conversion share count are not consistent; verify the executed offering terms.
- Management reported effective disclosure controls and no significant changes in internal control over financial reporting. The company stated that pending legal matters were not expected to materially affect the financial statements.
Important facts for investors to verify
- Whether cash burn and planned clinical spending remain consistent with the stated 12-month runway, including the net proceeds actually available from the October financing.
- The exact preferred-stock conversion terms and total potential dilution from the October financing, outstanding warrants, options, and grants.
- CLR 131 trial enrollment, safety, response durability, and the basis for dose selection and future study plans.
- Whether the company can secure additional financing in 2018 and the terms or potential strategic concessions required.